FULC vs. JANX, ETNB, ADPT, DYN, SPRY, EVO, TVTX, ANIP, MESO, and OCUL
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Janux Therapeutics (JANX), 89bio (ETNB), Adaptive Biotechnologies (ADPT), Dyne Therapeutics (DYN), ARS Pharmaceuticals (SPRY), Evotec (EVO), Travere Therapeutics (TVTX), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.
Fulcrum Therapeutics vs. Its Competitors
Fulcrum Therapeutics (NASDAQ:FULC) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, community ranking, profitability, media sentiment, analyst recommendations, risk and institutional ownership.
Fulcrum Therapeutics has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Fulcrum Therapeutics' return on equity of -7.31% beat Janux Therapeutics' return on equity.
Fulcrum Therapeutics has a beta of 2.41, meaning that its stock price is 141% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the S&P 500.
Janux Therapeutics has lower revenue, but higher earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.
Fulcrum Therapeutics received 58 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 70.97% of users gave Janux Therapeutics an outperform vote while only 61.82% of users gave Fulcrum Therapeutics an outperform vote.
Fulcrum Therapeutics currently has a consensus price target of $6.29, indicating a potential downside of 7.97%. Janux Therapeutics has a consensus price target of $95.25, indicating a potential upside of 274.12%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Janux Therapeutics is more favorable than Fulcrum Therapeutics.
89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 7.0% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 8.1% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Janux Therapeutics had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 10 mentions for Janux Therapeutics and 9 mentions for Fulcrum Therapeutics. Janux Therapeutics' average media sentiment score of 1.13 beat Fulcrum Therapeutics' score of 1.09 indicating that Janux Therapeutics is being referred to more favorably in the news media.
Summary
Janux Therapeutics beats Fulcrum Therapeutics on 12 of the 19 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulcrum Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FULC) was last updated on 6/12/2025 by MarketBeat.com Staff
